11 research outputs found
Molecular Gastronomy in Spain
[EN] Beyond the overwhelming international success of Ferrán Adria, Spain has been one of the countries with a more active implication in molecular gastronomy as a scientific discipline but also in the use of ingredients, technologies, and equipment from the scientificand technological universe in the culinary area. Nowadays, this is a well-established discipline in Spain, with a number of research groups covering related topics, several companies commercializing appliances and additives worldwide, and renowned
international chefs and many restaurants and companies committed
to the collaboration with scientists for facing the future of
Spanish gastronomyThe authors would like to thank the Ministerio de Ciencia e Innovación (Spain) for funding the Collaborative Network “INDAGA” (AGL2007-28589- E/ALI; AGL2009-05765-E), which enabled their collaboration.García Segovia, P.; Garrido, MD.; Vercet Tormo, A.; Arboleya, JC.; Fiszman Dal Santo, S.; Martínez Monzó, J.; Laguarda, S.... (2014). Molecular Gastronomy in Spain. Journal of Culinary Science and Technology. 12(4):279-293. https://doi.org/10.1080/15428052.2014.914813S27929312
Acute Myocardial Infarct Size Is Related to Periodontitis Extent and Severity
Curves of degree 6 in the complex projective space can be interpreted as surfaces. These sur-faces can have holes, how many holes a surface has is called its genus. This thesis will investigate exactly what genera these surfaces can have. First, an upper bound for the genus is found, which turns out to be 4. Then, examples of curves of each genera are found and we conclude that it is possible to construct sextic space curves of all genera up to 4.Kurvor av grad 6 i det komplexa projektiva rummet kan tolkas som ytor. Dessa ytor kan ha hål och hur många hål en yta har kallas för ytans genus. Denna uppsats undersöker exakt vilka genus som dessa ytor kan ha. Först bestäms en övre gräns för deras genus, denna övre begränsning visar sig vara 4. Sedan hittas exempel på kurvor för varje genus och vi drar slutsatsen att det är möjligt att skapa sjättegradsrymdkurvor av varje genus upp till och med 4
The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury
Neuropathic pain is one of the most severe forms of chronic pain caused by the direct injury of the somatosensory system. The current drugs for treating neuropathies have limited efficacies or show important side effects, and the development of analgesics with novel modes of action is critical. The identification of endogenous anti-nociceptive factors has emerged as an attractive strategy for designing new pharmacological approaches to treat neuropathic pain. Cortistatin is a neuropeptide with potent anti-inflammatory activity, recently identified as a natural analgesic peptide in several models of pain evoked by inflammatory conditions. Here, we investigated the potential analgesic effect of cortistatin in neuropathic pain using a variety of experimental models of peripheral nerve injury caused by chronic constriction or partial transection of the sciatic nerve or by diabetic neuropathy. We found that the peripheral and central injection of cortistatin ameliorated hyperalgesia and allodynia, two of the dominant clinical manifestations of chronic neuropathic pain. Cortistatin-induced analgesia was multitargeted, as it regulated the nerve damage-induced hypersensitization of primary nociceptors, inhibited neuroinflammatory responses, and enhanced the production of neurotrophic factors both at the peripheral and central levels. We also demonstrated the neuroregenerative/protective capacity of cortistatin in a model of severe peripheral nerve transection. Interestingly, the nociceptive system responded to nerve injury by secreting cortistatin, and a deficiency in cortistatin exacerbated the neuropathic pain responses and peripheral nerve dysfunction. Therefore, cortistatin-based therapies emerge as attractive alternatives for treating chronic neuropathic pain of different etiologies
Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis
Lysine specific demethylase 1 (LSD1; also known as KDM1A), is an epigenetic modulator that modifies the histone methylation status. KDM1A forms a part of protein complexes that regulate the expression of genes involved in the onset and progression of diseases such as cancer, central nervous system (CNS) disorders, viral infections, and others. Vafidemstat (ORY-2001) is a clinical stage inhibitor of KDM1A in development for the treatment of neurodegenerative and psychiatric diseases. However, the role of ORY-2001 targeting KDM1A in neuroinflammation remains to be explored. Here, we investigated the effect of ORY-2001 on immune-mediated and virus-induced encephalomyelitis, two experimental models of multiple sclerosis and neuronal damage. Oral administration of ORY-2001 ameliorated clinical signs, reduced lymphocyte egress and infiltration of immune cells into the spinal cord, and prevented demyelination. Interestingly, ORY-2001 was more effective and/or faster acting than a sphingosine 1-phosphate receptor antagonist in the effector phase of the disease and reduced the inflammatory gene expression signature characteristic ofEAE in the CNS of mice more potently. In addition, ORY-2001 induced gene expression changes concordant with a potential neuroprotective function in the brain and spinal cord and reduced neuronal glutamate excitotoxicity-derived damage in explants. These results pointed to ORY-2001 as a promising CNS epigenetic drug able to target neuroinflammatory and neurodegenerative diseases and provided preclinical support for the subsequent design of early-stage clinical trials